Company Description
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease.
The company also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders, including obesity and type 2 diabetes.
In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease.
The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021.
Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2022 |
| IPO Date | Oct 25, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Jeffrey Finer |
Contact Details
Address: 250 East Grand Avenue South San Francisco, California 94080 United States | |
| Phone | 650 338 3533 |
| Website | septerna.com |
Stock Details
| Ticker Symbol | SEPN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001984086 |
| CUSIP Number | 81734D104 |
| ISIN Number | US81734D1046 |
| Employer ID | 84-3891440 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeffrey T. Finer M.D., Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Elizabeth P. Bhatt M.B.A., M.S. | Chief Operating Officer |
| Dr. Jae B. Kim FACC, M.D. | Chief Medical Officer |
| Dr. Robert J. Lefkowitz M.D. | Co-Founder and Member of Cross-Functional Scientific and Drug Discovery Advisory Board |
| Dr. Arthur Christopoulos BPHARM, Ph.D. | Co-Founder and Member of Cross-Functional Scientific and Drug Discovery Advisory Board |
| Dr. Patrick Sexton Ph.D. | Co-Founder and Member of Cross-Functional Scientific and Drug Discovery Advisory Board |
| Gilbert M. Labrucherie C.F.A., J.D. | Chief Financial Officer |
| Richard Hansen Ph.D. | Vice President of Technology |
| George Xu Ph.D. | Senior Director of Corporate Development and Portfolio Strategy |
| Samira Shaikhly | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2025 | SCHEDULE 13G/A | Filing |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 18, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |